สมัครสมาชิก

The Group’s in-licensed product Adasuve® (Loxapine for Inhalation) obtained Drug Registration Certificate

28 November 2023, Lee’s Pharmaceutical Holdings Limited (“Lee’s Pharm” or the “Group”, HKEx:00950) announced that the Drug Registration Certificate for Adasuve® (Loxapine for Inhalation) had been obtained from the China National Medical Products Administration (“NMPA”) for the acute treatment of agitation associated with schizophrenia or bipolar disorder in adults.

ดาวน์โหลดข่าวฉบับเต็ม (PDF)

ที่มา: Lee’s Pharmaceutical Holdings – News & Media

ข่าวสารอื่นๆ

Pre-IND meeting to communicate the combination of recombinant fully human anti- PD-L1 monoclonal antibody injection (ZKAB001 for short) and vaccinia GM-CSF/TK inactivated virus (Pexa-Vec, oncolytic virus)

ตุลาคม 21, 2019

Lee’s Pharm participated in BIOHK2024, focusing on rare disease drug innovation

กันยายน 16, 2024

⟨ Life and Health China Tour 2025 — Henan Province⟩ Treprostinil Injection (芮旎爾®) Launching Ceremony cum Pulmonary Hypertension Summit Forum

พฤษภาคม 29, 2025

HKBIO and Lee’s Pharm Mask Donation Campaign

มีนาคม 10, 2020

Zhaoke Lian Fa, a subsidiary of Lee’s Pharm was honoured with “Excellence Enterprise Award of Gold Pilot Award 2022”

มีนาคม 23, 2023

Zhaoke Ophthalmology and Nevakar Entered Into A License Agreement for NVK-002 — Introducing The Eye Treatment For Slowing The Progression of Myopia in Children in Greater China, SEA and South Korea Markets

ตุลาคม 20, 2020

Thai